To understand what psilocybin does in the brain, it helps to follow the molecule from the moment it is swallowed to the receptors it eventually binds to. The pharmacology is well established in its broad outlines, even where the mechanistic details remain debated, and tracing the journey is the clearest way to see why the experience has the shape it does. This article walks through that journey in a way that does not assume a background in chemistry or neuroscience.
It is an explainer about how the compound behaves in the body, not a guide to using it. Where it mentions timing or dose-related effects, the point is to describe the pharmacokinetics that researchers measure, not to instruct anyone on use.
What psilocybin is
Psilocybin is a tryptamine, a class of organic compounds built around an indole ring with a side chain. The neurotransmitter serotonin is also a tryptamine, which is part of why psilocybin acts on the serotonin system in the brain. That structural similarity is the key to its activity. Psilocybin itself is what pharmacologists call a prodrug, a compound that is not itself responsible for the biological effect but is converted in the body into the active substance. The active substance is psilocin, structurally very similar to psilocybin but with a hydroxyl group where psilocybin has a phosphate ester. The conversion happens almost immediately after ingestion, primarily in the gut and liver.
For practical purposes, the active compound in the brain is psilocin. Psilocybin is simply the form in which the compound exists in the mushroom and the form in which it enters the body. The metabolic conversion is fast and reliable enough that the distinction is often glossed over, but it matters for understanding the pharmacokinetics, because the body is really responding to psilocin throughout.
Absorption and onset
Psilocybin is well absorbed from the digestive tract. The onset of effects typically begins twenty to sixty minutes after oral ingestion on an empty stomach, with food in the stomach delaying onset somewhat. The acute effects peak roughly ninety minutes to two hours after ingestion and then decline over the following four to six hours, with most people reporting a substantial return toward baseline six to eight hours after a moderate dose.
This relatively long duration is a function of psilocin's metabolism, which proceeds at a moderate pace through enzymes in the liver. The compound is eventually broken down primarily into psilocin glucuronide, a water-soluble metabolite excreted in urine, and most of an ingested dose is cleared within twenty-four hours. Individual variation in onset, peak, and duration is substantial. Body size, metabolism, what is in the stomach, and individual differences in liver enzyme activity all affect the timeline, so two people taking the same amount can have quite different experiences in terms of timing alone.
Receptor binding
Once in the bloodstream, psilocin crosses the blood-brain barrier and reaches its primary site of action in the central nervous system. That site is the family of serotonin receptors, particularly the 5-HT2A subtype, with secondary action on 5-HT2C and several others. The 5-HT2A receptor is densely expressed in the cortex, especially in the prefrontal cortex and other association areas, which are the brain regions involved in higher-order functions like planning, reflection, abstract thought, and the sense of self. Psilocin's action on these receptors is what produces the characteristic perceptual, cognitive, and emotional effects of the experience.
Importantly, psilocin is an agonist at 5-HT2A, meaning it binds to the receptor and activates it, mimicking serotonin's natural action but in a different pattern. Its selectivity and binding kinetics differ from serotonin's, which is why the cellular consequences differ from what ordinary serotonin signaling produces. It is not simply flooding the system with extra serotonin. It is keying into one specific lock in an unusual way.
Pull quote: What you swallow is not quite what acts on your brain. Psilocybin is a prodrug, converted within minutes into psilocin, which then keys into one specific serotonin receptor in an unusual way.
What activated 5-HT2A receptors do
Activation of 5-HT2A receptors on cortical neurons increases their excitability. The neurons fire more readily in response to inputs they would normally largely ignore, which is part of why psychedelic experiences often involve perceiving connections between things that ordinarily seem unrelated, or being struck by ordinary stimuli as unusually meaningful. The filter that normally keeps most of this in the background is turned down.
At the network level, 5-HT2A activation appears to disrupt the normal coordination patterns of major brain networks, particularly the default mode network, the constellation of regions most active during self-referential thought and mind-wandering. The default mode network's coordinated activity is reduced under psilocybin, while communication between networks that ordinarily do not interact much increases. These network-level changes, which we cover in depth in our article on the default mode network, are thought to underlie the experiences characteristic of the state, the dissolution of the ordinary sense of self, the novel associative connections, and the altered perception of self in relation to environment.
Other pharmacological effects
Beyond the central effects, psilocin has peripheral effects mediated by serotonin receptors in other tissues. Cardiovascular effects are mild but real, with modest increases in heart rate and blood pressure typical during the acute phase. These are generally well tolerated by people without underlying cardiovascular disease but can be relevant for those with significant cardiac conditions. Pupillary dilation is reliable and visible. Mild nausea is common early in the experience, particularly with mushroom material that contains other compounds beyond psilocybin. Some people experience headaches the day after a session, which appear related to the cardiovascular effects and tend to resolve with hydration.
The 5-HT2B receptor, distinct from the 5-HT2A receptor that mediates the psychoactive effects, is also activated by psilocin to a modest degree. Chronic stimulation of 5-HT2B receptors has been associated with cardiac valve problems in other contexts, notably with the withdrawn diet drug fenfluramine. For occasional doses this is not a meaningful concern, but it is part of the safety analysis for repeated dosing patterns, which is one reason the microdosing literature treats long-term frequency with caution.
Tolerance and cross-tolerance
Psilocybin produces rapid tolerance. A second dose taken within twenty-four hours of the first will typically produce a substantially weaker effect, and doses on consecutive days produce minimal effect after the first. The tolerance is thought to involve down-regulation of 5-HT2A receptors in response to acute activation, the cells pulling receptors inside and becoming temporarily less responsive. Cross-tolerance exists with other classic psychedelics, LSD, mescaline, and DMT, that act on the same receptor system, so someone who has recently taken LSD will find a psilocybin dose produces a weaker than usual effect, and the reverse holds too. The tolerance dissipates over days, with full sensitivity typically returning within a week to ten days. We cover this in detail in our article on tolerance and cross-tolerance.
What pharmacology does and does not explain
Pharmacology can describe what the molecule does at the level of receptor binding and network activity. It is genuinely informative about why the experience has certain general features, the visual changes, the duration, the altered sense of self, and about what the relevant safety considerations are. On those questions it is solid ground.
What pharmacology does not explain is why the specific content of psilocybin experiences varies so substantially between people, sessions, and contexts. Two people with similar pharmacology can have very different experiences with the same dose. The mechanisms that translate altered cortical activity into specific subjective experience involve many factors, set, setting, prior life experience, and expectation, that are not captured by the pharmacology alone. This is part of why psilocybin research is unusual in psychiatry. The pharmacology sets the stage, but it does not fully determine the play, and pretending otherwise would overstate what the molecule alone can tell us.